- Home
- TJGC vs SER Comparison
TJGC vs SER Comparison
Compare TJGC & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | SER |
|---|---|---|
| Founded | 2022 | 2017 |
| Country | Hong Kong | United States |
| Employees | N/A | 13 |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0M | 19.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TJGC | SER |
|---|---|---|
| Price | $1.08 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 222.7K | ★ 7.7M |
| Earning Date | 08-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $1.22 |
| 52 Week High | $1.55 | $7.92 |
Technical Indicators
Market Signals| Indicator | TJGC | SER |
|---|---|---|
| Relative Strength Index (RSI) | 73.60 | 48.66 |
| Support Level | $1.01 | $1.66 |
| Resistance Level | $1.17 | $3.16 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 99.27 | 27.22 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.